You might be interested in
Break It Down
Break it Down: Bioxyne goes gummy gaga in Australian first
Health & Biotech
Island lifts 50pc on $3.5m capital raise and Phase 2a/b dengue trial progress
Health & Biotech
Stockhead TV
Stockhead’s Fraser Palamara sits down with Bioxyne’s (ASX:BXN) founder and CEO Sam Watson to get the short end of the long story on the company’s latest news.
Bioxyne, the parent company of Breath Life Sciences, has manufactured and delivered Australia’s first pharmaceutical cannabis pastilles.
It’ll supply the goods around the world, and recently received its first commercial purchase orders.
Tune in to hear Bioxyne’s Sam Watson on the business’ interest, how it can grow, and more.
This video was developed in collaboration with Bioxyne, a Stockhead advertiser at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.